[Hypolipidaemic agents (author's transl)].
Since clofibrate was discovered, a number of compounds have been made available for the treatment of hyperlipoproteinaemias. Their principal pharmacological and therapeutic properties are summarized in this paper. Other compounds are now under pre-clinical or clinical studies, including probucol which is reviewed in this issue.
D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D002784:Cholesterol / Q000378:metabolism; D002792:Cholestyramine Resin / Q000494:pharmacology; D002994:Clofibrate / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000145:classification* / Q000494:pharmacology / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood; D009539:Nicotinic Acids / Q000494:pharmacology; D011341:Probucol / Q000494:pharmacology
D000960:Hypolipidemic Agents; D008074:Lipoproteins; D009539:Nicotinic Acids; D002792:Cholestyramine Resin; D002784:Cholesterol; D002994:Clofibrate; D011341:Probucol
Les médicaments hypolipidémiants.